Osteologix Inc has received a Notice of Allowance from the US Patent and Trademark Office for its US Patent Application Number 11/579,773 titled 'High Yield and Rapid Synthesis Methods for Producing Metallo-Organic Salts' reporting allowance of claims covering certain manufacturing processes for NB S101 (strontium malonate), the company's lead osteoporosis drug candidate. The company expects the patent will issue in the second half of 2009; the patent's 20-year term would expire in 2025.
This patent allowance expands the company's patent portfolio that also includes the recently upheld European patent in which the European Patent Office (EPO) maintained the validity of the company's European Patent No. EP 1,534,305 B9, 'Treating Cartilage and Bone Conditions with Water Soluble Strontium Salts'. This patent offers protection for the use of NB S101 (strontium malonate) for the treatment of osteoporosis and related conditions while confirming that the innovative product, NB S101, demonstrated a significant increase in bioavailability over the EMEA approved Protelos (strontium ranelate).
Osteologix is a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases, such as osteoporosis.